查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1458449

糖尿病黄斑部水肿市场规模：按治疗类型、应用和最终用户划分 - 区域前景、竞争策略和细分市场预测（截至 2033 年）

Diabetic Macular Edema Market Size- By Treatment Type, By Application, By End User- Regional Outlook, Competitive Strategies and Segment Forecast to 2033
出版日期: | 出版商: SPER Market Research Pvt. Ltd. | 英文 235 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计2033年，全球糖尿病黄斑部水肿市场规模将成长至152.5亿美元，复合年增长率为4.69%。

糖尿病性视力丧失的主要原因之一是糖尿病性黄斑部水肿（DME）。 DME 被认为是由视网膜脉管系统渗透性引起的。黄斑部水肿的严重程度与糖尿病视网膜病变有关。糖尿病黄斑部水肿的病理和发展背后的分子机制很复杂，需要更深入地了解这种疾病的分子途径和病理。

本报告调查了全球糖尿病黄斑部水肿市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测、各个细分市场和地区的详细分析、竞争格局以及主要企业。的。

目录

第一章简介

第二章调查方法

第三章执行摘要

第四章市场动态

  • 驱动因素、限制因素、机会与挑战分析
  • COVID-19 对市场的影响

第五章 市场变数与展望

  • SWOT分析
  • PESTEL分析
  • 波特五力分析
  • 热图分析

第六章 竞争状况

  • 製造地、销售区域、产品类型分布
  • 併购、联盟、产品发布、合作

第七章全球糖尿病黄斑部水肿市场：依治疗类型

  • 全球市占率及预测
  • 药物治疗
  • 雷射治疗

第八章全球糖尿病黄斑部水肿市场：依应用分类

  • 全球市占率及预测
  • 黄斑部水肿
  • 黄斑部病变

第九章全球糖尿病黄斑部水肿市场：依最终用户分类

  • 全球市占率及预测
  • 医院
  • 诊所
  • 其他的

第10章全球糖尿病黄斑部水肿市场预测

  • 市场规模/市场占有率

第十一章全球糖尿病黄斑部水肿市场：依治疗类型

  • 市场规模/市场占有率趋势/预测

第十二章全球糖尿病黄斑部水肿市场：依应用分类

  • 市场规模/市场占有率趋势/预测

第 13 章全球糖尿病黄斑部水肿市场：依最终用户分类

  • 市场规模/市场占有率趋势/预测

第14章全球糖尿病黄斑部水肿市场：按地区

  • 市场规模/市场占有率趋势/预测
  • 亚太地区
  • 欧洲
  • 中东/非洲
  • 北美洲
  • 拉丁美洲

第十五章 公司简介

  • Alimera Sciences Inc.
  • Abbvie Inc.
  • Bayer AG
  • Bausch Health Companies Inc.
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Kubota Pharmaceutical Hodlings Co. Ltd.
  • Novartis AG
  • Regen X Bio Inc.
  • Regeneron Pharmaceuticals Inc.
  • 其他的

第十六章简称

第十七章 参考链接

第18章结论

第十九章 研究范围

简介目录
Product Code: PHAR2403

Diabetic Macular Edema Market Introduction and Overview

According to SPER market research, 'Diabetic Macular Edema Market Size- By Treatment Type, By Application, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033' state that the Global Diabetic Macular Edema Market is predicted to reach USD 15.25 billion by 2033 with a CAGR of 4.69%.

One of the most frequent reasons of diabetic vision loss is diabetes-related macular edema (DME). It is believed to be brought on by the hyper permeability of the retinal vasculature. Macular edema and the severity of diabetic retinopathy are related. Due to the complexity of the pathophysiology and molecular mechanisms behind the development of diabetic macular edema, a deeper understanding of the disease's molecular pathways and pathogenesis is required.

The COVID-19 virus first surfaced in December 2019 and has since spread to nearly every country in the world, prompting the World Health Organisation (WHO) to declare a public health emergency. The global healthcare system has been badly disrupted in the aftermath of the coronavirus pandemic due to the financial crisis and the delay in delivering specialist healthcare while prioritising COVID-19 treatments.

Scope of the Report:

Report Metric Details

Market size available for years 2020-2033

Base year considered 2023

Forecast period 2024-2033

Segments covered By Treatment Type, By Application, By End User

Regions covered North America, Asia-Pacific, Latin America, Middle East & Africa and Europe

Companies Covered Abbvie Inc., Alimera Sciences Inc., Bausch Health Companies Inc., Bayer AG, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Kubota Pharmaceutical,Hodlings Co. Ltd., Novartis AG, Regen X Bio Inc., Regeneron Pharmaceuticals Inc.,

Global Diabetic Macular Edema Market Segmentation:

By Treatment Type: Based on the Treatment Type, Global Diabetic Macular Edema Market is segmented as; Drug Therapy and Laser Treatment.

By Application: Based on the Application, Global Diabetic Macular Edema Market is segmented as; Macular Edema and Macular Degeneration.

By End User: Based on the End User, Global Diabetic Macular Edema Market is segmented as; Hospital, Clinics and Other.

Table of Contents

1. Introduction

  • 1.1. Scope of the report
  • 1.2. Market segment analysis

2. Research Methodology

  • 2.1. Research data source
    • 2.1.1. Secondary Data
    • 2.1.2. Primary Data
    • 2.1.3. SPER's internal database
    • 2.1.4. Premium insight from KOL's
  • 2.2. Market size estimation
    • 2.2.1. Top-down and Bottom-up approach
  • 2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

  • 4.1. Driver, Restraint, Opportunity and Challenges analysis
    • 4.1.1. Drivers
    • 4.1.2. Restraints
    • 4.1.3. Opportunities
    • 4.1.4. Challenges
  • 4.2. COVID-19 Impacts of the Global Diabetic Macular Edema Market

5. Market variable and outlook

  • 5.1. SWOT Analysis
    • 5.1.1. Strengths
    • 5.1.2. Weaknesses
    • 5.1.3. Opportunities
    • 5.1.4. Threats
  • 5.2. PESTEL Analysis
    • 5.2.1. Political Landscape
    • 5.2.2. Economic Landscape
    • 5.2.3. Social Landscape
    • 5.2.4. Technological Landscape
    • 5.2.5. Environmental Landscape
    • 5.2.6. Legal Landscape
  • 5.3. PORTER's Five Forces
    • 5.3.1. Bargaining power of suppliers
    • 5.3.2. Bargaining power of buyers
    • 5.3.3. Threat of Substitute
    • 5.3.4. Threat of new entrant
    • 5.3.5. Competitive rivalry
  • 5.4. Heat Map Analysis

6. Competitive Landscape

  • 6.1. Global Diabetic Macular Edema Market Manufacturing Base Distribution, Sales Area, Product Type
  • 6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Diabetic Macular Edema Market

7. Global Diabetic Macular Edema Market, By Treatment Type (USD Million)

  • 7.1. Global Diabetic Macular Edema Market Value Share and Forecast, By Treatment Type, 2024-2033
  • 7.2. Drug Therapy
  • 7.3. Laser Treatment

8. Global Diabetic Macular Edema Market, By Application (USD Million)

  • 8.1. Global Diabetic Macular Edema Market Value Share and Forecast, By Application, 2024-2033
  • 8.2. Macular Edema
  • 8.3. Macular Degeneration

9. Global Diabetic Macular Edema Market, By End User (USD Million)

  • 9.1. Global Diabetic Macular Edema Market Value Share and Forecast, By End User, 2024-2033
  • 9.2. Hospital
  • 9.3. Clinics
  • 9.4. Others

10. Global Diabetic Macular Edema Market Forecast, 2020-2033 (USD Million)

  • 10.1. Global Diabetic Macular Edema Market Size and Market Share

11. Global Diabetic Macular Edema Market, By Treatment Type 2020-2033 (USD Million)

  • 11.1. Global Diabetic Macular Edema Market Size and Market Share By Treatment Type (2020-2026)
  • 11.2. Global Diabetic Macular Edema Market Size and Market Share By Treatment Type (2027-2033)

12. Global Diabetic Macular Edema Market, By Application, 2020-2033 (USD Million)

  • 12.1. Global Diabetic Macular Edema Market Size and Market Share By Application (2020-2026)
  • 12.2. Global Diabetic Macular Edema Market Size and Market Share By Application (2027-2033)

13. Global Diabetic Macular Edema Market, By End User, 2019-2033 (USD Million)

  • 13.1. Global Diabetic Macular Edema Market Size and Market Share By End User (2020-2026)
  • 13.2. Global Diabetic Macular Edema Market Size and Market Share By End User (2027-2033)

14. Global Diabetic Macular Edema Market, By Region, 2019-2033 (USD Million)

  • 14.1. Global Diabetic Macular Edema Market Size and Market Share By Region (2020-2026)
  • 14.2. Global Diabetic Macular Edema Market Size and Market Share By Region (2027-2033)
  • 14.3. Asia-Pacific
    • 14.3.1. Australia
    • 14.3.2. China
    • 14.3.3. India
    • 14.3.4. Japan
    • 14.3.5. South Korea
    • 14.3.6. Rest of Asia-Pacific
  • 14.4. Europe
    • 14.4.1. France
    • 14.4.2. Germany
    • 14.4.3. Italy
    • 14.4.4. Spain
    • 14.4.5. United Kingdom
    • 14.4.6. Rest of Europe
  • 14.5. Middle East and Africa
    • 14.5.1. Kingdom of Saudi Arabia
    • 14.5.2. United Arab Emirates
    • 14.5.3. Rest of Middle East & Africa
  • 14.6. North America
    • 14.6.1. Canada
    • 14.6.2. Mexico
    • 14.6.3. United States
  • 14.7. Latin America
    • 14.7.1. Argentina
    • 14.7.2. Brazil
    • 14.7.3. Rest of Latin America

15. Company Profile

  • 15.1. Alimera Sciences Inc.
    • 15.1.1. Company details
    • 15.1.2. Financial outlook
    • 15.1.3. Product summary
    • 15.1.4. Recent developments
  • 15.2. Abbvie Inc.
    • 15.2.1. Company details
    • 15.2.2. Financial outlook
    • 15.2.3. Product summary
    • 15.2.4. Recent developments
  • 15.3. Bayer AG
    • 15.3.1. Company details
    • 15.3.2. Financial outlook
    • 15.3.3. Product summary
    • 15.3.4. Recent developments
  • 15.4. Bausch Health Companies Inc.
    • 15.4.1. Company details
    • 15.4.2. Financial outlook
    • 15.4.3. Product summary
    • 15.4.4. Recent developments
  • 15.5. F. Hoffmann-La Roche Ltd
    • 15.5.1. Company details
    • 15.5.2. Financial outlook
    • 15.5.3. Product summary
    • 15.5.4. Recent developments
  • 15.6. GlaxoSmithKline Plc
    • 15.6.1. Company details
    • 15.6.2. Financial outlook
    • 15.6.3. Product summary
    • 15.6.4. Recent developments
  • 15.7. Kubota Pharmaceutical Hodlings Co. Ltd.
    • 15.7.1. Company details
    • 15.7.2. Financial outlook
    • 15.7.3. Product summary
    • 15.7.4. Recent developments
  • 15.8. Novartis AG
    • 15.8.1. Company details
    • 15.8.2. Financial outlook
    • 15.8.3. Product summary
    • 15.8.4. Recent developments
  • 15.9. Regen X Bio Inc.
    • 15.9.1. Company details
    • 15.9.2. Financial outlook
    • 15.9.3. Product summary
    • 15.9.4. Recent developments
  • 15.10. Regeneron Pharmaceuticals Inc.
    • 15.10.1. Company details
    • 15.10.2. Financial outlook
    • 15.10.3. Product summary
    • 15.10.4. Recent developments
  • 15.11. Others

16. List of Abbreviations

17. Reference Links

18. Conclusion

19. Research Scope